

## CURRICULUM VITAE: Ferran Torres, MD, PhD

Spanish; born April 11<sup>th</sup>, 1964

**Main Address**            Biostatistics and Data Management Core Facility  
IDIBAPS (Institut d'investigacions Biomèdiques August Pi i Sunyer)  
Hospital Clinic Barcelona  
183, Mallorca Street. Floor -1. Office #60. 08036 Barcelona  
Phone: +34 932 279 328 / Fax: +34 932 279 877  
[Ferran.Torres@idibaps.org](mailto:Ferran.Torres@idibaps.org) / [www.idibaps.org](http://www.idibaps.org) // [www.hospitalclinic.org](http://www.hospitalclinic.org)

**Secondary Address**        Biostatistics Unit. Faculty of Medicine.  
Universitat Autònoma de Barcelona (UAB)  
08193 Bellaterra (Barcelona). Spain  
Phone: +34 93 581 23 46 / 19 03. Fax: +34 93 581 23 44  
[Ferran.Torres@uab.es](mailto:Ferran.Torres@uab.es) / [www.uab.es](http://www.uab.es)

**Miscellanea**                Short presentation at: <http://ferran.torres.name/about-me/>  
ResearchGate => [https://www.researchgate.net/profile/Ferran\\_Torres](https://www.researchgate.net/profile/Ferran_Torres)  
ResearcherId: D-1296-2011 => <http://www.researcherid.com/rid/D-1296-2011>  
ORCID: 0000-0002-7355-7913 => <http://orcid.org/0000-0002-7355-7913>  
SCOPUS: 7102336718 => <http://www.scopus.com/authid/detail.url?authorId=7102336718>

### EDUCATION

1993-1998    PhD in Medicine. Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona.

Doctoral thesis: "Methodological and statistical issues in the design of sequential clinical trials".

Director: Prof. Victor Moreno (Unit of Biostatistics, Department of Public Health. School of Medicine Universitat Autònoma de Barcelona. Tutorship: Prof. Josep Torrent. Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona

Defended in March 1998: "*Excel.lent Cum Laude.*"

1989-92    Medical Specialist in Clinical Pharmacology, Hospital Universitari Vall d'Hebron, Barcelona.

1982-88    Degree in Medicine and Surgery. Universitat Autònoma de Barcelona, Barcelona.

### PROFESSIONAL EXPERIENCE

- Current position

Since 2014            Chair of the "*Programme on Methodology, Statistics and Data Management*" in the SCReN network (Spanish Clinical Research Network), funded by the ISCIII (<http://www.isciii.es> , Institute of Health Carlos III)

ISCIII is the main Public Research Entity funding, managing and carrying out biomedical research in Spain.

SCReN is the Spanish member of the ECRIN network (European Clinical Research Infrasturcture Network <http://www.ecrin.org> )

Since 2013-            Permanent External Reviewer of the ECRIN standard procedures

Since Juny-2009        Member of the Biostatistics Group (BSWP) at the EMA (European Medicines Agency).

Since Juny-2008        Member of the SAWP (Scientific Advice Working Group) of the EMA (European Medicines Agency).

Since 2007            Head of the Biostatistics and Data Management Core Facility. Hospital Clínic. Barcelona.

- Methodological and statistical support to other Hospital Medical Services for the design, conduction, analyses and reporting of clinical trials and research projects.
- Member of the ECRIN network; member of the Data Management Working Group.

- Researcher at several independent research projects.
- Since 1999      Statistical consultant for the Clinical Evaluation section, Agencia Española del Medicamento y Productos Sanitarios (AEMPS):
- Elaboration and discussion of methodological guidelines: rapporteur “CPMP/EWP/1776/99 Points to Consider on Missing Data”, and member of the working group discussion “Points to Consider on the Calculation and Reporting of the Prevalence of a Condition for Orphan Designation” and “CHMP/EWP/83561/05. Guideline on Clinical Trials in Small Populations”.
  - Support to AEM and Efficacy Working Party expert for the writing of methodological guidelines, Committee for Proprietary Medicinal Products, European Agency for the Evaluation of Medicinal Products (EMA).
  - Support to the Spanish assessors in the review of dossiers of register and scientific advice since 2000.
  - Education: Training on methodological and statistical issues to the AEMPS since 2002. Teacher at the Assessor Training meeting at EMA, 2002. Workshop on Methodological Aspects of Clinical Trials for Efficacy Evaluation in Small Populations: Sequential designs EMA 2002.
- Since 1994      Associate Professor, Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona (UAB).
- Teaching of statistics and methodology to undergraduate and post-graduate students.
- Since 1993      Senior Consultant at the Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona (UAB).
- Responsible for the methodological design and analysis of clinical trials (since 1993, more than 70 bioequivalence and phase I clinical trials, and more than 40 phase III-IV clinical trials.)
- Former experience
- 2004-2007      Senior Consultant. Clinical Pharmacology Department. Hospital Clínic Barcelona.
- 2002-2007      Member of the Ethic’s Committee at Institut Univeritari Dexeus (Barcelona)
- 1996-2002      Biometrics responsible, Clinical Pharmacology Department, Hospital de Sant Pau, Barcelona
- 1989-1992      Resident physician at of the Clinical Pharmacology Service. Ciutat Sanitària Universitària de la Vall d’Hebron (Barcelona).
- 1992              Stage at the General Directorate of Drugs and Health Products. Spanish Ministry of Health.
- 1992-1993      Granted at the Unit of Biostatistics. School of Medicine. Universitat Autònoma de Barcelona.
- Other
- Societies              Registered physician (Col·legi Oficial Metges de Barcelona) since 1988, No. 25820.
- Member of the Spanish Society of Clinical Pharmacology since 1990; Member of the Executive Committee since Oct 2002- current.
- Member of European Association of Clinical Pharmacology and Therapeutics.
- Member of XXI Congreso de la Sociedad Española de Farmacología Clínica (SEFC) 2008 Organizing Committee.
- Member of "Drug Information Association" (DIA) since 1993 up to date.
- Member of Biometría Clínica para la Investigación Farmacéutica Association since 1994.
- Languages              Spanish and Catalan: native languages.
- English: fluent spoken and written.

**Publications**

More than 130 published papers in indexed scientific journals with a cumulated IF of >600. Listing includes references from 2008 onwards.

**2014**

- Busquets C, Ojeda A, **Torres F**, Faulí A, Moreno LA, Bogdanovich A, Giménez-Milà M, Hernández-Cera C, Fàbregas N, Videla S. Desarrollo y validación de un algoritmo para identificar recidivas de cáncer a partir de bases de datos hospitalarias. *Rev Calidad Asistencial* 2014;29(4):229-236 doi: 10.1016/j.cali.2014.05.003
- Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Martí-Fàbregas J, Gállego J, Krupinski J, Gomis M, Cánovas D, Carné X, Deulofeu R, Román LS, Oleaga L, **Torres F**, Planas AM; URICO-ICTUS Investigators. . Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. . *Lancet Neurol*. 2014 May;13(5):453-60. doi: 10.1016/S1474-4422(14)70054-7. Epub 2014 Apr 2.
- Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, **Torres F**, Mateo GM, Villarroya J, de Los Santos I, Domingo JC, Villarroya F, Rio LD, Estrada V, Giralt M. . Effects of Switching from Stavudine to Raltegravir on Subcutaneous Adipose Tissue in HIV-Infected Patients with HIV/HAART-Associated Lipodystrophy Syndrome (HALS). A Clinical and Molecular Study. *PLoS One*. 2014 Feb 26;9(2):e89088. doi: 10.1371/journal.pone.0089088. eCollection 2014.
- Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, **Torres F**, Mateo MG, Villarroya J, Lamarca K, Domingo JC, Vidal F, Villarroya F, Giralt M. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz. *J Acquir Immune Defic Syndr*. 2014 Aug 15;66(5):457-65. doi: 10.1097/QAI.0000000000000205
- Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; **D:A:D study Group**. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. *BMC Nephrol*. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51
- Muñoz X, Sánchez-Ortiz M, **Torres F**, Villar A, Morell F, Cruz MJ. Diagnostic yield of specific inhalation challenge in hypersensitivity pneumonitis. *Eur Respir J*. 2014 Aug 19. pii: erj00607-2014
- Pallero M, Puy C, Güell R, Pontes C, Martí S, **Torres F**, Antón A, Muñoz X. Ambulatory adaptation to noninvasive ventilation in restrictive pulmonary disease: A randomized trial with cost assessment. *Respir Med*. 2014 May 2. pii: S0954-6111(14)00163-2. doi: 10.1016/j.rmed.2014.04.016. [Epub ahead of print]
- Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin C, El-Sadr W, d'Arminio Monforte A, Phillips A, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren J, Law M; **D:A:D study group**. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. *HIV Med*. 2014 May 19. doi: 10.1111/hiv.12162. [Epub ahead of print]. IF:X Q: citations:
- Pontes C, Vives R, **Torres F**, Panés J. Safety and Activity of Dersalazine Sodium in Patients with Mild-to-moderate Active Colitis: Double-blind Randomized Proof of Concept Study. *Inflamm Bowel Dis*. 2014 Sep 3. [Epub ahead of print]. IF:X Q: citations:
- Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió I Torrenta L, Brieua L, Cano A, Carmona O, Saiz A, **Torres F**, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. *Mult Scler*. 2014 May;20(6):717-25. doi: 10.1177/1352458513508835. Epub 2013 Oct 21. IF:4.472 Q:1 citations:0
- Reig M, **Torres F**, Rodríguez-Lope C, Forner A, Llarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. . *J Hepatol*. 2014 Apr 2. pii: S0168-8278(14)00211-6. doi: 10.1016/j.jhep.2014.03.030.
- Salazar F, Doñate M, Boget T, Bogdanovich A, Basora M, **Torres F**, Gracia I, Fàbregas N. Relationship between intraoperative regional cerebral oxygen saturation trends and cognitive decline after total knee replacement: a post-hoc analysis. *BMC Anesthesiol*. 2014 Jul 21;14:58. doi: 10.1186/1471-2253-14-58. eCollection 2014.
- Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; **D:A:D Study Group**. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. *Lancet*. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

**2013**

- Blanco I, Santos S, Gea J, Güell R, **Torres F**, Gimeno-Santos E, Rodriguez DA, Vilaró J, Gómez B, Roca J, Barberà JA. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. *Eur Respir J*. 2013 Feb 21. [Epub ahead of print]. Impact\_factor: 5.895
- Dodd CN, Romio SA, Black S, Vellozzi C, Andrews N, Sturkenboom M, Zuber P, Hua W, Bonhoeffer J, Buttery J, Crawford N, Deceuninck G, de Vries C, De Wals P, Gimeno MV, Heijbel H, Hughes H, Hur K, Hviid A, Kelman J, Kilpi T, Chuang SK, Macartney K, Rett M, Lopez-Callada VR, Salmon D, Sanchez FG, Sanz N, Silverman B, Storsaeter J, Thirugnanam U, van der Maas N, Yih K, Zhang T, Izurieta H; **Global H1N1 GBS Consortium**. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. *Vaccine*. 2013 Sep 13;31(40):4448-58. doi: 10.1016/j.vaccine.2013.06.032. Epub 2013 Jun 14. Impact\_factor: 3.492.
- Domingo P, Cabeza Mdel C, **Torres F**, Salazar J, Gutierrez Mdel M, Mateo MG, Martínez E, Domingo JC, Fernandez I, Villarroya F, Ribera E, Vidal F, Baiget M. Association of Thymidylate Synthase Polymorphisms with Acute Pancreatitis and/or Peripheral Neuropathy in HIV-Infected Patients on Stavudine-Based Therapy. *PLoS One*. 2013;8(2):e57347. doi: 10.1371/journal.pone.0057347. Epub 2013 Feb 28. Impact\_Factor: 4.41
- Domingo P, Mateo MG, Pruvost A, **Torres F**, Salazar J, Gutierrez MD; Ma Carmen Cabeza, Domingo JC, Fernandez I, Villarroya F, Vidal F, Baiget M, de la Calle-Martín O. Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B\*40 : 01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. *PLoS One*. 2013 Jun 26;8(6):e67035. Print 2013.
- Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, Soler J, **Torres F**, Campistol JM, Martinez-Castelao A; ESHOL Study Group. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *J Am Soc Nephrol*. 2013 Feb;24(3):487-97. doi: 10.1681/ASN.2012080875. Epub 2013 Feb 14. Impact\_Factor: 9.663
- Malouf J, Digregorio S, Rio LD, **Torres F**, Marin AM, Farrerons J, Herrera S, Domingo P. Fat Tissue Measurements by Dual-Energy X-Ray Absorptiometry: Cross-Calibration of 3 Different Fan-Beam Instruments. *J Clin Densitom*. 2013 Apr-Jun;16(2):212-22. doi: 10.1016/j.jocd.2012.04.003. Epub 2012 Jun 13. Impact\_Factor: 1.713
- Moizé V, Andreu A, Flores L, **Torres F**, Ibarzabal A, Delgado S, Lacy A, Rodríguez L, Vidal J. Long-Term Dietary Intake and Nutritional Deficiencies following Sleeve Gastrectomy or Roux-En-Y Gastric Bypass in a Mediterranean Population. *J Acad Nutr Diet*. 2013 Mar;113(3):400-10. doi:

10.1016/j.jand.2012.11.013. Impact\_Factor: 3.797

Palomar M, Alvarez-Lerma F, Riera A, Díaz MT, **Torres F**, Agra Y, Larizgoitia I, Goeschel CA, Pronovost PJ. Impact of a National Multimodal Intervention to Prevent Catheter-Related Bloodstream Infection in the ICU: The Spanish Experience. *Crit Care Med*. 2013 Oct;41(10):2364-72. doi: 10.1097/CCM.0b013e3182923622. Impact\_factor: 6.37.

Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió I, Torrenta L, Brieva L, Cano A, Carmona O, Saiz A, **Torres F**, Giner P, Nos C, Massuet A, Montalbán X, Martínez-Cáceres E, Costa J. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. *Mult Scler*. 2013 Oct 21. [Epub ahead of print]. Impact\_factor: 4.472.

Reig M, Rimola J, **Torres F**, Darnell A, Lope CR, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. *Hepatology*. 2013 Jun 20. doi: 10.1002/hep.26586. [Epub ahead of print]. Impact\_factor: 11.67.

Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; on behalf of the **D:A:D Study Group**. Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Study. *J Infect Dis*. 2013 Feb 27. [Epub ahead of print]. Impact\_Factor: 6.41

Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; **D:A:D Study Group**. Associations between immune depression and cardiovascular events in HIV infection. *AIDS*. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3. ]. Impact\_Factor: 6.407.

**Torres F**, Pontes C. [Missing data: Warrant for search and capture.] *Med Clin (Barc)*. 2013 May 22. doi:pil: S0025-7753(13)00260-1. 10.1016/j.medcli.2013.04.001. [Epub ahead of print]. Impact\_factor: 1.385.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, Wit SD, Phillips A, Lundgren JD, Sabin CA; **D:A:D Study Group**. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. *BMC Infect Dis*. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471. Impact\_factor: 3.03.

## 2012

Cabrera-López C, Martí T, Catalá V, **Torres F**, Mateu S, Ballarín J, Torra R. Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial. *Orphanet J Rare Dis*. 2012 Nov 11;7:87. doi: 10.1186/1750-1172-7-87. Impact\_Factor: 5.074

Domingo P, Guardiola JM, Salazar J, **Torres F**, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca K, Fontanet A, Martin J, Muñoz J, Vidal F, Baiget M. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. *Antimicrob Agents Chemother*. 2012 Jun;56(6):2987-93. Impact\_Factor: 4.8

Llupia A, Vilella A, Costas L, Díez C, **Torres F**, Yagüe J, Massó M, Muñoz A, Mensa J. Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted?. *Vaccine*. 2012;30:2382-2386. Impact\_Factor: 3.62

Malouf J, Digregorio S, Rio LD, **Torres F**, Marin AM, Farrerons J, Herrera S, Domingo P. Fat Tissue Measurements by Dual-Energy X-Ray Absorptiometry: Cross-Calibration of 3 Different Fan-Beam Instruments. *J Clin Densitom*. 2012 Jun 13. [Epub ahead of print]. Impact\_Factor: 2.39

Margalef P, Fernández-Majada V, Villanueva A, García-Carbonell R, Iglesias M, López L, Martínez-Iniesta M, Villà-Freixa J, Mulero MC, Andreu M, **Torres F**, Mayo MW, Bigas A, Espinosa L. A novel truncated form of IKK $\alpha$  is responsible for nuclear IKK activity in colorectal cancer. *Cell Rep*. 2012 Oct 25;2(4):840-54. doi: 10.1016/j.celrep.2012.08.028. Epub 2012 Oct 4. Impact\_Factor:

Moizé V, Gluck ME, **Torres F**, Andreu A, Vidal J, Allison K. Transcultural adaptation of the Night Eating Questionnaire (NEQ) for its use in the Spanish population. *Eat Behav*. 2012 Aug;13(3):260-3. Epub 2012 Mar 7. Impact\_Factor: 0

Muñoz X, Sanchez-Vidaurre S, Roca O, **Torres F**, Morell F, Cruz MJ. Bronchial inflammation and hyperresponsiveness in well controlled asthma. *Clin Exp Allergy*. 2012 Sep;42(9):1321-8. Impact\_Factor: 4.08

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; **D:A:D Study Group**. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. *J Int AIDS Soc*. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426. Impact\_Factor: 3.256

Solà R, Valls RM, Godàs G, Perez-Busquets G, Ribalta J, Girona J, Heras M, Cabré A, Castro A, Domenech G, **Torres F**, Masana L, Anglés N, Reguant J, Ramírez B, Barriach JM. Cocoa, hazelnuts, sterols and soluble fiber cream reduces lipids and inflammation biomarkers in hypertensive patients: a randomized controlled trial. *PLoS ONE* 7(2): e31103. doi:10.1371/journal.pone.0031103. Impact\_Factor: 4.41

Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, D'Arminio Monforte A, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD; **D:A:D Study Group**. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. *J Infect Dis*. 2012;205(4):535-9. Impact\_Factor: 6.4.

## 2011

Amaro S, Urra X, Gómez-Choco M, Obach V, Cervera A, Vargas M, **Torres F**, Rios J, Planas AM, Chamorro A. Uric Acid Levels Are Relevant in Patients With Stroke Treated With Thrombolysis. *Stroke*. 2011 Jan;42(1 Suppl):S28-32.

Amor AJ, Ricart MJ, **Torres F**, de Hollanda AM, Yago G, Ara P, Esmatjes E. Prevalencia y control de los factores de riesgo cardiovascular en pacientes con diabetes mellitus tipo 1 candidatos a trasplante renopancreático entre los años 1999 y 2010. *Av Diabetol*. 2011;27(4):137-142.

Cabrera López C, Martí T, Catalá V, **Torres F**, Mateu S, Ballarín Castán J, Torra Balcells R. Effects of Rapamycin on Angiomyolipomas in Patients with Tuberous Sclerosis. *Nefrología*. 2011;31(3):292-298

Cánovas M, **Torres F**, Domenech G, Cebrecos J, Pelagio P, Manríquez M, Martínez G, Arcabell M, Cabré F. Bioequivalence evaluation of two dosage forms of olanzapine 10 mg formulations in healthy volunteers. *Arzneimittelforschung* 2011;61(2):75-79

Cánovas M, **Torres F**, Domenech G, Cebrecos J, Pelagio P, Martínez G, Polonio F, Cabré F. Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers. *Arzneimittelforschung*. 2011;61(9):489-93

Carrera G, García-Albeniz X, Ayuso JR, Aparicio J, Castells A, Codony-Servat J, Feliu J, Fuster D, Gallego R, Pagés M, **Torres F**, Maurel J. Design And Endpoints Of Clinical And Translational Trials In Advanced Colorectal Cancer. A Proposal From Grupo Español Multidisciplinar En Cancer Digestivo (Gemcad). *Review on Recent Clinical Trials*. 2011 Jan 14. [Epub ahead of print].

**Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.** The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study. *J Infect Dis.* 2011;204(4):521-5.

Domingo P, Cabeza MC, Pruvost A, **Torres F**, Salazar J, Gutierrez MD, Mateo MG, Fontanet A, Fernandez I, Domingo JC, Villarroya F, Vidal F, Baiget M. Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. *Antimicrob Agents Chemother.* 2011 Jan 31. [Epub ahead of print].

Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD; CoDe Working Group; **D:A:D Study Group.** The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. *Epidemiology.* 2011;22(4):516-23.

Llupia A, Vilella A, Costas L, Díez C, **Torres F**, Yagüe J, Massó M, Muñoz A, Mensa J. Can the response to 23-valent pneumococcal vaccine in splenectomised patients be predicted? *Vaccine.* 2011 Sep 28.

Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Foraster A, Soler J, Galceran JM, Martinez-Castelao A; Online Hemodiafiltration Study Group from the Catalan Society of Nephrology.

Masclans JR, Roca O, Muñoz X, Pallisa E, **Torres F**, Rello J, Morell F. QUALITY OF LIFE, PULMONARY FUNCTION AND TOMOGRAPHIC SCAN ABNORMALITIES AFTER AN ACUTE RESPIRATORY DISTRESS SYNDROME. *Chest.* 2011 Feb 17.

Moizé V, Deulofeu R, **Torres F**, de Osaba JM, Vidal J. Nutritional Intake and Prevalence of Nutritional Deficiencies Prior to Surgery in a Spanish Morbidly Obese Population. *Obes Surg.* 2011 Feb 6. [Epub ahead of print].

Obach V, Oleaga L, Urrea X, Macho J, Amaro S, Capurro S, Gomez-Choco M, San Román L, Cervera A, Blasco J, Vargas M, **Torres F**, Chamorro A. Multimodal CT-Assisted Thrombolysis in Patients With Acute Stroke: A Cohort Study. *Stroke.* 2011 Feb 17.

Ohmann C, Kuchinke W, Canham S, Lauritsen J, Salas N, Schade-Brittinger C, Wittenberg M, McPherson G, McCourt J, Gueyffier F, Lorimer A, **Torres F**, Working Group On Data Centres E. Standard requirements for GCP-compliant data management in multinational clinical trials. *Trials.* 2011 Mar 22;12(1):85. [Epub ahead of print] doi:10.1186/1745-6215-12-85

Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M; **D:A:D Study Group.** Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(\*). *HIV Med.* 2011 Aug;12(7):412-21

Salazar F, Doñate M, Boget T, Bogdanovich A, Basora M, **Torres F**, Fàbregas N. Intraoperative warming and post-operative cognitive dysfunction after total knee replacement. *Acta Anaesthesiol Scand.* 2011 Feb;55(2):216-22. doi: 10.1111/j.1399-6576.2010.02362.x.PMID: 21226864.

## 2010

Amaro S, Urrea X, Gómez-Choco M, Obach V, Cervera A, Vargas M, **Torres F**, Rios J, Planas AM, Chamorro A. Uric Acid Levels Are Relevant in Patients With Stroke Treated With Thrombolysis. *Stroke* December 16, 2010, doi: 10.1161/STROKEAHA.110.596528

Carrión JA, **Torres F**, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. *Hepatology.* 2010 Jan;51(1):23-34.

Cervera A, Planas AM, Justicia C, Urrea X, Jensenius JC, **Torres F**, Lozano F, Chamorro A. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. *Plos One.* 2010;5(2):e8433.

Crespo A, Muñoz X, **Torres F**, Martí S, Ferrer J, Morell F. Noninvasive home mechanical ventilation in elderly patients. *Gerontology.*2010;56(2):150-6.

Cruz N, Sanchez-Moreno J, **Torres F**, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. *Int J Neuropsychopharmacol.* 2010 Feb;13(1):5-14.

**Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group,** Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J, Collins S, Dabis. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. *Antivir Ther.* 2010;15(8):1077-86.

Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Worm SW, Friis-Møller N, Sabin CA, Sjøel A, Lundgren JD, Salbøl-Brandt R, Rickenbach M, Pezzotti P, Krum E, Gras L, Balestre E, Sundström A, Delforge M, Fontas E, **Torres F**, P. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. *AIDS* 2010; 24(10):1537-48.

Escorsell A, **Torres F**, Bookman I, Mas A, Rios J, Fernandez J, Gines R. Early identification of prognostic factors of death in acute-on-chronic liver failure. *Journal of Hepatology.* 2010;52(Suppl.1):S72-S72

Esteva-Font C, Wang X, Ars E, Guillén-Gómez E, Sans L, González Saavedra I, **Torres F**, Torra R, Masilamani S, Ballarín JA, Fernández-Llama P. Are Sodium Transporters in Urinary Exosomes Reliable Markers of Tubular Sodium Reabsorption in Hypertensive Patients? *Nephron Physiol.* 2010 Jan 12;114(3):p25-p34.

Friis-Møller N, Thiébaud R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; **DAD study group.** Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. *Eur J Cardiovasc Prev Rehabil.* 2010;17(5):491-501.

Izquierdo I, Borja J, Rovira S, Pelagio P, **Torres F**, Cebrecos J, García-Rafanell J. Comparative bioavailability study of triflusal oral solution vs. Triflusal capsules in healthy subjects. *Arzneimittelforschung* 2010;60(1):36-41.

Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, Leizorovicz A, Schade-Brittinger C, Wittenberg M, Voko Z, Gaynor S, Cooney M, Doran P, Maggioni A, Lorimer A, **Torres F**, McPherson G, Charwill J, Hellström M, Lejeune S. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. *Trials.* 2010;11:79.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; **SPiRAL Study Group.** Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPiRAL study. *AIDS.* 2010;24(11):1697-707.

Roca O, Masclans JR, Muñoz X, **Torres F**, Morell F, Rello J. Health related quality of life in ARDS survivors: importance of the early measurement. *Intensive Care Medicine* 2010;36(Suppl.2):S229-S229.

Roca O, Riera J, **Torres F**, Masclans JR. High-flow oxygen therapy in acute respiratory failure. *Respir Care.* 2010 Apr;55(4):408-13.

Solà R, Bruckert E, Valls RM, Narejos S, Luque X, Castro-Cabezas M, Doménech G, **Torres F**, Heras M, Farrés X, Vaquer JV, Martínez JM, Almaraz MC, Anguera A. Soluble fibre (Plantago ovata husk) reduces plasma low-density lipoprotein (LDL) cholesterol, triglycerides, insulin, oxidised LDL and systolic blood pressure in hypercholesterolaemic patients: A randomised trial. *Atherosclerosis*. 2010;211(2):630-7.

Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, **Torres F**, Cardona PJ, Costa J. Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI. *Vaccine*. 2010 Jan 22;28(4):1106-16.

Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; **D:A:D study group**. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. *AIDS*. 2010;28;24(3):427-35.

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J, for the **D:A:D Study Group**. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. *J Infect Dis*. 2010 Feb 1;201(3):318-30.

## 2009

Fabregas N, Salazar F, Doñate M, **Torres F**, Boget T. Regional Brain O2 Desaturation Is an Independent Risk Factor for Postoperative Cognitive Dysfunction. *J. Neurosurg Anesthesiol* 2009;21(4) October Abstract A1413 .

Cánovas M, Delgadillo J, **Torres F**, Riba N, Cebrecos J, Pelagio P, Cabré F. Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. *Int J Clin Pharmacol Ther* 2009;47(2):124-31

Carne X, **Rios J**, **Torres F**. Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care. *Methods Find Exp Clin Pharmacol*. 2009 Oct;31(8):533-40.

**The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)**. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). *Circulation*. 2009;119(6):805-11

Cruz N, Sanchez-Moreno J, **Torres F**, Goikolea JM, Valentí M, Vieta E. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. *Int J Neuropsychopharmacol*. 2009 Jul 29:1-10

Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study. Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Pradier C, Thiebaut R, Law M, Rickenbach M, Stephane DW, Lundgren JD, Møller NF, **Data Collection on Adverse Events of Anti-HIV Drugs (The D:A:D study)**. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. *Diabetes Care* 2009;32(3):474-80

De Gottardi A, Thévenot T, Spahr L, Morard I, Bresson-Hadni S, **Torres F**, Giostra E, Hadengue A. Risk of Complications After Abdominal Paracentesis in Cirrhotic Patients: A Prospective Study. *Clin Gastroenterol Hepatol*. 2009;7(8):906-9

Domingo P, Suarez-Lozano I, **Torres F**, Pomar V, Ribera E, Galindo MJ, Cosin J, Garcia-Alcalde ML, Vidal F, Lopez-Aldegue J, Roca B, Gonzalez J, Lozano F, Garrido M; on behalf of the VACH Cohort Study Group. Bacterial Meningitis in HIV-1-Infected Patients in the Era of Highly Active Antiretroviral Therapy. *J Acquir Immune Defic Syndr*. 2009;51(5):582-7.

Fontseré N, Esteve V, Saurina A, Pou M, Barba N, Deulofeu R, Di Gregorio S, Del Rio LM, **Rios J**, **Torres F**, Maduell F, Campistol JM, Ramírez de Arellano M. The Search for a New Marker of Renal Function in Older Patients with Chronic Kidney Disease Stages 3-4: Usefulness of Cystatin C-Based Equations. *Nephron Clin Pract*. 2009 Apr 24;112(3):c164-c170.

Guevara M, Baccaro ME, Torre A, Gómez-Ansón B, **Ríos J**, **Torres F**, Rami L, Monté-Rubio GC, Martín-Llahí M, Arroyo V, Ginès P. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. *Am J Gastroenterol*. 2009 Jun;104(6):1382-9.

Monzón S, Arrondo E, Bartra J, **Torres F**, Basagaña M, SanMiguel MM, Alonso R, Cisteró-Bahima A. Conjunctivitis and Total IgE in Lacrimal Fluid: Lacrytest Screening. *Journal of Allergy* 2009, Article ID 518903, 6 pages, doi:10.1155/2009/518903

Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernández-Majada V, Grilli A, López-Bigas N, Bellora N, Albà MM, **Torres F**, Duñach M, Sanjuan X, Gonzalez S, Gridley T, Capella G, Bigas A, Espinosa L. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. *PNAS* 2009; 106: 6315-6320

**The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study)**. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).

## 2008

Trullàs JC, Barril G, Cofan F, Moreno A, Cases A, Fernandez-Lucas M, Martinez-Ara J, Ceballos M, Garcia-de-Diego J, Muñoz ML, Molina J, Martínez-Castelao A, González-García J, Miró JM; and the **Spanish HIV Infection in Dialysis Study Group**. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. *AIDS Res Hum Retroviruses*. 2008;24(10):1229-1235.

Fontseré N, Bonal J, Salinas I, Ramírez de Arellano M, Ríos J, **Torres F**, Sanmartí A, Romero R. Is the New Mayo Clinic Quadratic Equation Useful for the Estimation of Glomerular Filtration Rate in Type 2 Diabetic Patients? *Diabetes Care* 2008 Diciembre,31,12,2265-67

Domingo P, Suarez-Lozano I, Teira R, Lozano F, Terrón A, Viciano P, González J, Galindo MJ, Guijo P, Vergara A, Cosin J, Ribera E, Roca B, Garcia-Alcalde ML, Sánchez T, **Torres F**, Lacalle JR and Garrido M. Dyslipidemia and Cardiovascular Disease Risk Factor Management in HIV-1-Infected Subjects Treated with HAART in the Spanish VACH Cohort. *The Open AIDS Journal*, 2008, 2, 26-38.

Atienzar MC, Palanca JM, **Torres F**, Borrás R, Gil S, Esteve I. A randomized comparison of levobupivacaine, bupivacaine and ropivacaine with fentanyl, for labor analgesia. *International Journal of Obstetric Anesthesia* 2008;17:106-111

Basagaña M, Bartolomé B, Pastor C, Torres F, Alonso R, Vivancos F, Cisteró-Bahima A. Allergy to Human Seminal Fluid: Cross-Reactivity with Dog Dander. *J Allergy Clin Immunol*. 2008 Jan;121(1):233-9. PMID: 18061650

- Domingo P, Suarez-Lozano I, **Torres F**, Teira R, Lopez Aldeguer J, Vidal F, Muñoz A, Viciano P, Lozano F, Vergara A, Roca B, Garcia A ML, Cosin J, Terron A, Galindo MJ, Geijo, P, Ribera, E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA Study, a non-randomized comparison from the VACH Cohort. *Journal of Antimicrobial Chemotherapy*, (2008) 61, 1348–1358. doi:10.1093/jac/dkn121. Advance Access publication 20 March 2008. PMID: 18356150
- Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, Ferro JM, Gomez-Anson B, Manubens JM, Martinez-Lage JM, Muñoz D, Peña-Casanova J, **Torres F** on behalf of the TRIMCI Study Group. A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment. *The TRIMCI Study*. *Alzheimer Dis Assoc Disord*. 2008 Jan-Mar;22(1):21-9. PMID: 18317243
- Muñoz X, **Torres F**, Sampol G, Rios J, Martí S, Escrich E. Accuracy and Reliability of Pulse Oximetry at Different PaCO<sub>2</sub> Levels. *Eur Respir J* 2008 May 14. doi:10.1183/09031936.00126507 [Epub ahead of print]. PMID: 18480106
- Salas-Salvadó J, Farrés X, Luque X, Narejos S, Borrell M, Basora J, Anguera A, **Torres F**, Bulló M, Balanza R for the Fiber in Obesity-Study Group\*. Effect of a Mixture of Fibres on Body Weight and Metabolic Variables in Overweight or Obese Patients. *British Journal of Nutrition Br J Nutr*. 2008 Jun;99(6):1380-7. Epub 2007 Nov 22. PMID: 18031592
- D:A:D Study Group**, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. *Lancet*. 2008 Apr 26;371(9622):1417-26. E pub 2008 Apr 2. PMID: 18387667
- Data Collection on Adverse Events of Anti-HIV Drugs Study Group**, Sabin CA, d'Arminio Monforte A, Friis-Møller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. *Clin Infect Dis*. 2008 Apr 1;46(7):1101-10. PMID: 18461712
- De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Casanave C, El-Sadr W, Monforte A, Fontas E, Law MG, Friis-Møller N, Phillips A; **Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study**. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. *Diabetes Care* 2008; 31(6):1224-9. PMID: 18268071
- Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; **Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group**. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. A Monforte, D Abrams, C Pradier, R Weber, P Reiss, F Bonnet, O Kirk, M Law, S De Wit, N Friis-Møller, AN Phillips, CA Sabin, JD Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. *AIDS*. 2008 Oct 18;22(16):2143-53. PMID: 18832878
- Strategies for Management of Anti-Retroviral Therapy/INSIGHT; **DAD Study Groups**. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. *The SMART/INSIGHT and the D:A:D study groups*. *AIDS*.2008, 22:F17-F24. PMID: 18753925.

### **Participation in independent investigation projects with competitive financing**

PROJECT TITLE: SCReN. Spanish Clinical Research Network

FINANCING ENTITY: ISCIII (Spain)

PRINCIPAL RESEARCHER for the Biostats Program: Ferran Torres Benítez

DURATION: from 2014-2018

PROJECT TITLE: Advances in Small Trials dEsign for Regulatory Innovation and eXcelence (ASTERIX)

FINANCING ENTITY FP7-HEALTH-2013-INNOVATION-1

PRINCIPAL RESEARCHER WP5: Ferran Torres Benítez

DURATION: from 2013-2017

PROJECT TITLE: European Clinical Research Infrastructures Network and biotherapies facilities in Spain- ECRIN. ECRIN-Preparation Phase Infrastructure

FINANCING ENTITY: Comissió Europea. 7 Programa Marco

DURATION: from 2009 to 2011

PRINCIPAL RESEARCHER: Jaques Demotes/ Spanish Coordinator: Xavier Carné

PROJECT TITLE: European Clinical Research Infrastructures Network and biotherapies facilities in Spain- ECRIN). ECRIN-Transnational Working Groups (TWG, 2006-2008)

FINANCING ENTITY: Comissió Europea. 6 Programa Marco

DURATION: from 2006 to 2008

PRINCIPAL RESEARCHER: Jaques Demotes/ Coord.nacional: Xavier Carné / Data Management: Ferran Torres

PROJECT TITLE: Consolidación proyecto European Clinical Research Infrastructures Network and biotherapies en España

FINANCING ENTITY: MEC. Dirección general de Política y Tecnología

DURATION: from 2007 to 2009

PRINCIPAL RESEARCHER: Xavier Carné.

PROJECT TITLE: Efectividad de Los Inhibidores del Eje Renina-Angiotensina en Pacientes con Diabetes Mellitus Tipo 2 e Hipertensión Arterial en Catalunya. Estudio de Cohortes IERACAT.

FINANCING ENTITY: FIS ECO7/90010

DURATION: FROM 2007 TO 2009

PRINCIPAL RESEARCHER: Rosa Morros Pedrós

PROJECT TITLE: Tratamiento de los Tumores Vasculares de la Infancia y el Desarrollo con Bevacizumab  
FINANCING ENTITY: FIS EC07/90139  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Jaume Mora Graupera

PROJECT TITLE: Uricoictus-fase III. Estudio doble ciego, aleatorizado frente a vehículo de la eficacia clínica del tratamiento combinado con ácido úrico y RTPA administrados por vía intravenosa en pacientes con ictus isquémico de menos de 3 horas de evolución.  
FINANCING ENTITY: FIS EC07/90276  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Angel Chamorro Sanchez

PROJECT TITLE: Ensayo Clínico para Evaluar la Eficacia y Seguridad de la Rapamicina en los Angiomiolipomas en Pacientes con Esclerosis Tuberosa.  
FINANCING ENTITY: FIS EC07/90025  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Roser Torra Balcells

PROJECT TITLE: Utilidad de la detección precoz de la fibrilación auricular.  
FINANCING ENTITY: FIS PI070278  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Blanca Coll-Vinent Puig.

PROJECT TITLE: Estudio aleatorizado y abierto de la eficacia, seguridad y tolerabilidad de dosis repetidas de bevacizumab intravitreo en pacientes con edema macular uveítico  
FINANCING ENTITY: FIS  
DURATION: FROM 2008 TO 2011  
PRINCIPAL RESEARCHER: Alfredo Adán Civera

PROJECT TITLE: Ensayo de fase 2, brazo único, abierto, con irinotecan en combinación con CIS-Platino en pacientes pediátricos con gliomas de mal pronóstico  
FINANCING ENTITY: PFIS0067 EC08/00211  
DURATION: FROM 2008 TO 2011  
PRINCIPAL RESEARCHER: Ofelia Cruz.

PROJECT TITLE: Eficacia de dos sistemas de ahorro de oxígeno líquido en deambulación  
FINANCING ENTITY: FIS PI07/90074  
DURATION: FROM 2007 TO 2008  
PRINCIPAL RESEARCHER: Sergi Martí Beltran.

PROJECT TITLE: Estudio clínico y epidemiológico de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) en el paciente de edad avanzada en la era del tratamiento antiretroviral de gran actividad (TARGA). Estudio comparativo observacional de casos y controles en base de datos informatizada. Grupo Español de Estudios Observacionales VACH (Grupo VACH)  
FINANCING ENTITY: FIPSE.  
DURATION: FROM 2006 TO 2008.  
PRINCIPAL RESEARCHER: Dra. M<sup>a</sup> Antonia Sambeat/Dr. Pere Domingo.

PROJECT TITLE: Estrategias terapéuticas en Trastorno Depresivo Mayor resistente a tratamiento con Inhibidores Selectivos de la Recaptación de la Serotonina. Ensayo clínico pragmático, paralelo, aleatorizado con evaluación enmascarada  
FINANCING ENTITY: FIS (Cód. EudraCT: 2007-002130-11)  
DURATION: FROM 2007 TO 2009  
PRINCIPAL RESEARCHER: Dr Víctor Pérez Sola.

PROJECT TITLE: Training project to the Polish Regulatory Medical Agency.  
FINANCING ENTITY: FIIAPP (Fundación Internacional y para Ibero-América de Administración y Políticas Públicas).  
DURATION FROM 2004 TO 2004.  
PRINCIPAL RESEARCHER: Ferran Torres.

PROJECT TITLE: Data Collection on Adverse Events on anti-HIV Drugs (D:A:D Study).  
FINANCING ENTITY: FIPSE.  
DURATION FROM 2000 TO 2000.  
PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo.

PROJECT TITLE: Data Collection on Adverse Events on anti-HIV Drugs (D:A:D Study).  
FINANCING ENTITY: Committee for Proprietary Medicinal Products (CPMP).  
DURATION FROM 2000 TO 2000.  
PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo.

PROJECT TITLE: Estudio multicéntrico internacional para evaluar el riesgo cardiovascular asociado a la utilización de antiretrovirales en pacientes



VIH positivos.

FINANCING ENTITY: FIPSE.

DURATION FROM 2000 TO 2000.

PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo.

PROJECT TITLE: Estudio para evaluar el perfil de seguridad de los fármacos antirretrovirales en pacientes VIH positivos controlados en régimen ambulatorio.

FINANCING ENTITY: FIS (PI 99/0887)

DURATION FROM 1999 TO 2000.

PRINCIPAL RESEARCHER: Dr. Gonzalo Calvo

Ferran Torres